摘要
报道1例晚期肺腺癌患者奥希替尼治疗后耐药,基因检测示EGFR 19del/T790M/顺式C797S突变,联合使用奥希替尼、培美曲塞、贝伐珠单抗治疗有效。
One patient with advanced lung adenocarcinoma developed osimertinib resistance.After repeated genetic testing revealed EGFR 19 del/T790 M/cis-C797 S mutation,the patient was successfully treated with combined osimertinib,pemetrexed and bevacizumab.
作者
张航
袁霞
ZHANG Hang;YUAN Xia(Affiliated Huizhou Hospital,Sun Yat-Sen University,Huizhou 516000,China;Department of Oncology,Huizhou Muncipal Central Hospital,Huizhou 516000,China)
出处
《广东医科大学学报》
2020年第6期770-772,共3页
Journal of Guangdong Medical University
